Publications by authors named "Soichi Yagi"
Few studies have compared the efficacy and safety of Janus kinase (JAK) inhibitors in patients with ulcerative colitis (UC). We compared the real-world effectiveness and safety of tofacitinib (TOF) and filgotinib (FIL) as induction therapy for UC by propensity score-matching analysis. We enrolled 230 patients with active UC who received either TOF (n = 197) or FIL (n = 33) as induction therapy.
View Article and Find Full Text PDFBackground: Real-world data on tofacitinib (TOF) covering a period of more than 1 year for a sufficient number of Asian patients with ulcerative colitis (UC) are scarce.
Aim: To investigate the long-term efficacy and safety of TOF treatment for UC, including clinical issues.
Methods: We performed a retrospective single-center observational analysis of 111 UC patients administered TOF at Hyogo Medical University as a tertiary inflammatory bowel disease center.
Article Synopsis
- Filgotinib, a JAK 1 inhibitor approved for ulcerative colitis (UC), has limited real-world data on its effectiveness and safety, prompting a multicenter study of patients using it from March 2022 to September 2023.
- The study found that among 238 UC patients, clinical remission rates increased from 47% at 10 weeks to 64.6% at 58 weeks, with a median follow-up of 28 weeks showing 39.9% achieving remission.
- Adverse events were low, with only 1.3% developing herpes zoster, indicating that filgotinib has promising efficacy and safety in the real-world setting for UC treatment.*
Article Synopsis
- * Researchers reviewed medical records of patients who began TED treatment between 2020 and 2021, noting significant reductions in PS volume and the percentage of patients who had a decrease of at least 20% from the start of treatment.
- * Results showed a meaningful decrease in PS volume at 8 weeks, with a median drop from about 15,825 mL to 10,700 mL per week, and no serious adverse effects were reported during the study period.
Article Synopsis
- * A 76-year-old man experienced intestinal issues due to thrombosis of the portal and superior mesenteric veins caused by polycythemia vera, resulting in bowel obstruction and abdominal distention.
- * Surgical intervention was required after conservative treatments failed, revealing significant damage in the ileum, confirming ischemic enteritis linked to polycythemia vera; this is a previously unreported complication of the condition.